KR101800443B1 - Composition for enhancing innate immunity and antivirus comprising Asteris Radix extract as effective component - Google Patents
Composition for enhancing innate immunity and antivirus comprising Asteris Radix extract as effective component Download PDFInfo
- Publication number
- KR101800443B1 KR101800443B1 KR1020160035813A KR20160035813A KR101800443B1 KR 101800443 B1 KR101800443 B1 KR 101800443B1 KR 1020160035813 A KR1020160035813 A KR 1020160035813A KR 20160035813 A KR20160035813 A KR 20160035813A KR 101800443 B1 KR101800443 B1 KR 101800443B1
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- extract
- antiviral
- present
- group
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000002708 enhancing effect Effects 0.000 title abstract description 20
- 230000015788 innate immune response Effects 0.000 title abstract description 11
- 230000002155 anti-virotic effect Effects 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 13
- 241000700605 Viruses Species 0.000 claims description 54
- 241001529459 Enterovirus A71 Species 0.000 claims description 26
- 230000009385 viral infection Effects 0.000 claims description 24
- 241000700584 Simplexvirus Species 0.000 claims description 23
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 15
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000709661 Enterovirus Species 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 3
- 230000000843 anti-fungal effect Effects 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 38
- 208000015181 infectious disease Diseases 0.000 abstract description 32
- 206010010356 Congenital anomaly Diseases 0.000 abstract description 28
- 238000000034 method Methods 0.000 abstract description 14
- 239000004480 active ingredient Substances 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 208000035473 Communicable disease Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 230000003612 virological effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000002649 immunization Methods 0.000 abstract description 5
- 230000003053 immunization Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 230000000069 prophylactic effect Effects 0.000 abstract description 2
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000005090 green fluorescent protein Substances 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 32
- 235000020256 human milk Nutrition 0.000 description 25
- 210000004251 human milk Anatomy 0.000 description 25
- 241000712461 unidentified influenza virus Species 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 15
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 15
- 230000006698 induction Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 102100026720 Interferon beta Human genes 0.000 description 10
- 108090000467 Interferon-beta Proteins 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 239000013641 positive control Substances 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000002073 fluorescence micrograph Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 241000723353 Chrysanthemum Species 0.000 description 5
- 235000007516 Chrysanthemum Nutrition 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000709664 Picornaviridae Species 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 208000019061 glycogen storage disease due to GLUT2 deficiency Diseases 0.000 description 4
- 229940088592 immunologic factor Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000010359 Newcastle Disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 2
- 101710110781 Guanylate-binding protein 1 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000007578 Interferon Regulatory Factor-3 Human genes 0.000 description 2
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 2
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 2
- 101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001662414 Aster tataricus Species 0.000 description 1
- 229930188701 Astersaponin Natural products 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 241000204955 Colorado tick fever virus Species 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000709734 Coxsackievirus A24 Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 1
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 101710202180 Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 1
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- MBPOFHHSNKUQAY-UHFFFAOYSA-N Lachnophyllol acetate Natural products CCCC#CC#CC=CCOC(C)=O MBPOFHHSNKUQAY-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- XCDQFROEGGNAER-PFOIMGGJSA-N epi-Friedelanol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CC[C@H](O)[C@@H]1C XCDQFROEGGNAER-PFOIMGGJSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- FWTBRZMBHIYQSW-UHFFFAOYSA-N epifriedelanol Natural products CC1C(O)C(O)CC2C1(C)CCC3C2(C)CCC4(C)C5CC(C)(C)CCC5(C)C(O)CC34C FWTBRZMBHIYQSW-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 description 1
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- -1 pretilin Chemical class 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- HXPXUNQUXCHJLL-LZQQOHPBSA-N shionone Chemical compound C([C@]1(C)CC[C@@]23C)[C@](C)(CCC=C(C)C)CC[C@]1(C)[C@H]3CC[C@@]1(C)[C@H]2CCC(=O)[C@@H]1C HXPXUNQUXCHJLL-LZQQOHPBSA-N 0.000 description 1
- HXPXUNQUXCHJLL-UHFFFAOYSA-N shionone Natural products CC12CCC3(C)CC(C)(CCC=C(C)C)CCC3(C)C2CCC2(C)C1CCC(=O)C2C HXPXUNQUXCHJLL-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- UVYOXYJPADNJRE-UHFFFAOYSA-N trans-lachnophyllol Natural products CCCC#CC#CC=CCO UVYOXYJPADNJRE-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 약학 조성물, 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 건강기능식품, 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 사료 조성물 및 자완 추출물을 인간을 제외한 선천면역 증진이 필요한 동물에 투여하는 것을 포함하는 동물의 선천면역 증진 및 항바이러스 활성 증진 방법에 관한 것이다. 본 발명에 따른 선천면역 증진 및 항바이러스용 자완 조성물은 항바이러스 활성 및 선천면역 증진 효능을 나타내어, 박테리아 및 바이러스 감염성 질환의 예방 및 치료용으로 적용될 수 있고, 면역이 저하되거나 면역이 억제된 환자의 면역력 증진 및 조절을 위한 의약이나 건강기능식품, 및 동물의 항 질병 강화를 목적으로 하는 선천면역 증진 및 항바이러스용 사료 등으로 광범위하게 이용될 수 있다. 또한, 본 발명에 따른 선천면역 증진 및 항바이러스용 조성물은 독성이나 부작용을 거의 일으키지 않으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.The present invention relates to a concomitant immunization enhancing and antiviral pharmaceutical composition containing an extract of Jiaxiang as an active ingredient, a congenital immunization enhancer containing an extract of Jiaxiaxiang as an active ingredient, a health functional food for antivirus, The present invention relates to a method for promoting innate immunity and antiviral activity of an animal, which comprises administering a feed composition for promoting and antiviral use and an extract of a human being to an animal in need of innate immune enhancement other than human. The present invention relates to a composition for preventing and treating immunity and for preventing or treating a bacterial or viral infectious disease, which shows antiviral activity and innate immune enhancement efficacy, Medicines for improving and controlling immunity, functional foods for health, and congenital immunity enhancement and antiviral feeds for enhancing anti-disease of animals. In addition, since the composition for congenital immunity enhancement and antiviral according to the present invention hardly causes toxicity or side effects, it can be safely used for prolonged use even for prophylactic purposes.
Description
본 발명은 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스 조성물에 관한 것으로, 더욱 상세하게는 약학, 건강기능식품 또는 사료 조성물로 이용될 수 있는 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스 조성물에 관한 것이다.The present invention relates to a congenital immune enhancement and antiviral composition containing an extract of Zykylum javanica as an active ingredient, and more particularly to a connexin immunity enhancing and antiviral composition comprising an extract of Zyklon, which can be used as a pharmaceutical, a health functional food or a feed composition, And an antiviral composition.
면역은 태어날 때부터 지니고 있는 선천 면역(innate immunity)과 후천적으로 생활하면서 적응되어 얻어지는 획득 면역(acquired immunity)으로 구분될 수 있다. 선천 면역은 일명 '자연 면역'이라고도 하며, 항원에 대해 비특이적으로 반응하고, 특별한 기억작용은 없는 것을 특징으로 한다.Immunity can be divided into innate immunity, which is born from birth, and acquired immunity, which is obtained by adapting to life. Congenital immunity is also called "natural immunity" and is characterized by nonspecific responses to antigens and no special memory effect.
최근 들어, 생체 내 선천적 방어 면역시스템 중에서 인터페론(interferon)에 의해 유도되는 선천성 면역분야가 주목을 받고 있는데, 인터페론 매개 면역의 활성화는 다양한 전염병 병원체에 대한 근본적인 예방 방법이 될 수 있기 때문이다. 이에, 인터페론 활성화 기전 연구 및 인터페론을 유도시킬 수 있는 면역조절제제의 개발 연구가 활발하게 진행되고 있다. Recently, interferon-derived congenital immunity has been attracting attention in the in vivo innate defense immune system because activation of interferon-mediated immunity can be a fundamental preventive measure against various infectious pathogens. Therefore, studies on the interferon activation mechanism and development of immunoregulatory agents capable of inducing interferon have been actively conducted.
한편, 병원체의 감염에 따른 선천 면역의 방어 기작의 하나로 사이토카인 같은 면역 인자가 분비되는데, 이들에 의해 면역 반응이 일어나고 병원체에 대한 방어가 이루어진다. 따라서 선천 면역 반응을 유도함으로써 다양한 전염병 병원체 대한 예방 및 치료 방법이 될 수 있으며, 이를 유도시킬 수 있는 선천면역의 증진 제제에 대한 연구가 필요하다.On the other hand, immune factors such as cytokines are secreted as a defense mechanism against congenital immune due to infection of pathogens. Immune response occurs and defense against pathogens occurs. Therefore, it can be a preventive and therapeutic method for various infectious disease pathogens by inducing innate immune response, and it is necessary to study the enhancing agent for congenital immune which can induce it.
바이러스(virus)는 라틴어로 독성물질을 의미하며, 세균여과지(0.22㎛)를 통과하는 일군의 감염형 병원성 입자이다. 바이러스는 숙주세포의 종류에 따라 박테리오파지, 식물 바이러스, 동물 바이러스로 분류하기도 하며, 핵산의 종류에 따라 DNA 바이러스, RNA 바이러스로 분류할 수 있다. 최근 신종 플루, AI 및 구제역 등 다양한 바이러스 질병이 사회적으로 큰 문제를 일으켰으며, 이에 따라 바이러스 질병의 효과적인 대책에 대한 고민이 사회적으로 큰 관심을 불러일으키고 있다. Virus is a Latin word for toxic substances, a group of infectious pathogenic particles that pass through bacterial filter paper (0.22 μm). Viruses can be classified into bacteriophages, plant viruses, and animal viruses according to the type of host cell. DNA viruses and RNA viruses can be classified according to the type of nucleic acid. Recently, various virus diseases such as H1N1, AI, and foot-and-mouth disease have caused a great social problem, and the concern about effective measures for viral diseases has raised a great interest in society.
현재 바이러스성 질병을 예방하기 위한 가장 좋은 방법은 백신접종이지만, 바이러스에 의한 질병의 경우, 대체로 많은 바이러스 혈청형(아형) 생성 등에 따른 백신의 효율성 문제가 중요하게 제기되고 있다. 이러한 백신의 문제점을 보완해 줄 수 있는 바이러스 예방용 억제제의 개발 및 보급은 중요한 사항이며, 이를 위해 특히 바이러스에 대한 초기 방어시스템인 생체 내 선천적 면역시스템을 자극하여 개체 동물의 면역력을 높여주는 예방제제의 발굴 및 개발은 중요한 제제 개발 방법이 될 수 있다.Currently, vaccination is the best way to prevent viral diseases. However, in case of viral diseases, vaccine efficiency due to the generation of many viral serotypes (subtypes) is important. The development and dissemination of antiviral inhibitors that can overcome the problems of these vaccines is an important issue. For this purpose, a preventive agent that enhances immunity of an individual animal by stimulating the in vivo innate immune system, Can be an important method of drug development.
인플루엔자바이러스의 증식을 억제하는 대표적인 항바이러스 제제로는 아만타딘(amantadine)과 리만타딘(rimantadine)이 있으나, 이들 두 가지 항바이러스 제제들은 혈청형 A형 인플루엔자바이러스에만 효과적이며, M2 단백질이 없는 혈청형 B형 인플루엔자바이러스에는 효과가 없는 것으로 확인되었다. 또한, 아만타딘과 리만타딘은 사용 시 인플루엔자바이러스 M2 단백질의 이온채널기능에 영향을 미치지 못하는 변이 바이러스의 출현이 매우 쉽게 일어나는 단점이 있는 것으로 확인되고 있다. 이러한 단점을 보완하기 위하여 16종의 모든 혈청형 A형 인플루엔자바이러스와 혈청형 B형 인플루엔자바이러스에 효과적인 항바이러스 제제로 자나미비르(zanamivir)와 오셀타미비르(oseltamivir)가 개발되었다. 그러나 자나미비르는 흡입 및 정맥 투여해야 하는 단점이 있으며, 오셀타미비르는 경구투여가 가능하나 최근 내성 바이러스의 출현 보고와 경구투여 시 구토와 현기증 등의 부작용이 있어 단점으로 지적되고 있다.Amantadine and rimantadine are two typical antiviral agents that inhibit the proliferation of influenza virus. However, these two antiviral agents are effective only for the serotype A influenza virus and the serotype B It has been confirmed that it is not effective against influenza virus. In addition, amantadine and rimantadine have been found to have a disadvantage in that the mutant virus, which does not affect the ion channel function of the influenza virus M2 protein, appears very easily when used. To overcome this drawback, zanamivir and oseltamivir have been developed as antiviral agents effective against all 16 serotype A influenza viruses and serotype B influenza viruses. However, there is a disadvantage that Zanamivir should be administered by inhalation and intravenous injection. Ocelaminivir can be administered orally, but it is pointed out as a disadvantage due to recent reports of the emergence of resistant virus and side effects such as vomiting and dizziness when administered orally.
또한, 수포성구내염바이러스(Vesicular stomatitis virus)의 주된 통제 방법은 질병의 완전 치료가 불가능하기 때문에, 구제역과 마찬가지로 예방 및 차단 방역과 발생 지역 내 감수성 가축의 박멸이 최선의 방법이다.In addition, as the main control method of vesicular stomatitis virus is the inability to completely cure diseases, prevention and blocking prevention as well as foot-and-mouth disease and eradication of susceptible domestic livestock are the best methods.
또한, 뉴캐슬병 바이러스에 대한 백신은 크게 생독 백신과 사독 백신으로 구분되는데, 가장 널리 이용되어온 대표적인 뉴캐슬병 생독 백신주인 B1주와 La Sota주(Clone주 포함)는 백신 접종 반응을 유발하는 것으로 알려져 있으며, 전 세계적으로 사용되고 있는 뉴캐슬병 사독 백신인 다가 혼합 사독 오일 백신은 1회 백신 접종으로 3종 이상의 질병이 동시에 예방될 수 있으나, 산란계 농장의 경우 면역력 저하로 인한 뉴캐슬병 발생 피해 사례가 늘어나고 있다. In addition, vaccines against Newcastle Disease virus are classified into virulence vaccine and Sadox vaccine. It is known that the most widely used Newcastle disease virulence vaccine, B1 strain and La Sota strain (including Clone strain) The multivitamins combined vaccine oil vaccine, a Newcastle Disease vaccine that is used globally, can prevent three or more diseases at the same time by a single vaccination. However, in the case of laying hens farms, cases of Newcastle disease caused by immunity reduction are increasing.
또한, RNA 바이러스 가운데에서도 비교적 크기가 작은 바이러스들이 있다. 이들은 작다는 뜻의 'pico'라는 말과 'RNA'를 합쳐 피코나바이러스라고 부르며, 여기에 속한 바이러스들을 통틀어 피코나바이러스과 (Picona viridae)라고 부른다. 피코나바이러스 과에 속하는 엔테로바이러스는 무균성 수막염, 수족구병, 포진성 구협염, 확장성 심근염, 급성 출혈성 결막염 등의 다양한 임상증상을 일으키는 약 70가지 혈청형을 포함하고 있으며, 폴리오바이러스(Poliovirus), 콕사키바이러스(Cossackie virus) 및 에코바이러스(Echo virus)와 기타 엔테로바이러스로 분류된다. 엔테로바이러스의 직경이 20~30nm 정도이며, 단일 가닥의 RNA를 유전자로 가지고 있다. 대부분이 등뼈동물의 소화기관을 비롯하여 호흡기관 및 중추신경계까지 감염되지만 뚜렷한 증상을 나타내지 않는 경우가 많다. 콕사키바이러스(Coxsackie virus, CXV)는 피코나바이러스 과에 속하는 인간 엔테로바이러스(human enterovirus)로서, 크게 A형과 B형으로 구분된다(Pallansch MA and Roos RP, Fields Virology, 4th edi, pp723-775, 2001). There are also relatively small viruses among RNA viruses. These are called 'pico', which means small, and 'RNA', which are called picornaviruses. These viruses are called picona viridae. Enteroviruses belonging to the family of picornaviruses contain about 70 serotypes that cause various clinical symptoms such as aseptic meningitis, hand-foot disease, herpetic myelitis, acute hemorrhagic conjunctivitis and poliovirus. , Cossackie virus and echo virus, and other enteroviruses. The diameter of the enterovirus is about 20 to 30 nm, and it has a single strand RNA as a gene. Most are infected to the respiratory organs and central nervous system as well as the digestive organs of the vertebrates, but often do not show any obvious symptoms. Coxsackie virus (CXV) is a human enterovirus belonging to the picornaviridae, and is largely divided into A type and B type (Pallansch MA and Roos RP, Fields Virology, 4th edi, pp723-775 , 2001).
또한, 최근 세계 곳곳에서 고 위험성 엔테로바이러스 및 변종 바이러스(엔테로바이러스 71형(EV-71), 콕사키바이러스 A24 변이주)가 새롭게 발견되어 유행되고 있어 이를 조기에 탐지하기 위한 국가 간 공동감시체계 구축이 요구되고 있다. In recent years, high-risk enteroviruses and mutant viruses (enterovirus type 71 (EV-71) and coxsackievirus A24 mutant strains) have been newly discovered and become popular all over the world. Is required.
콕사키바이러스를 포함하는 엔테로바이러스는 척추동물의 소화기관을 비롯하여 호흡기관 및 중추신경계까지 감염되어 다양한 임상증상을 유발하기 때문에 국가 차원의 대책 마련이 시급히 요구되고 있으나 바이러스의 종류와 혈청형이 매우 다양하여 효과적인 상용화 백신이나 치료제가 개발되어 있지 못한 실정이다.Enteroviruses including Coxsackie virus are infected to respiratory organs and central nervous system including vertebrate animal digestive organs and cause various clinical symptoms. Therefore, it is urgently required to prepare countermeasures at the national level. However, the types and serotypes of viruses are very various Thus, effective commercialized vaccines and therapeutic agents have not been developed.
또한, 단순포진바이러스(Herpes Simplex Virus; 이하 HSV)는 헤르페스 바이러스 속에 속하는 DNA 바이러스로서 약 175nm의 크기를 가지는 비교적 큰 바이러스이며, 인간에게 널리 퍼져 있는 감염체이다. 단순포진 감염은 HSV 1형(이하, 'HSV-1'라 함) 및 HSV 2형(이하, 'HSV-2'라 함)의 감염으로써, 점막이나 피부를 침범하는 급성 수포성 질환이며 아토피가 있는 사람에게서 흔히 볼 수 있는 감염질환이다. HSV-1은 주로 입과 안구 주위에, HSV-2는 성기주위에 수포를 형성시킨다. 이러한 HSV의 감염은 면역기능이 저하되어 있는 환자들에게는 그 정도가 심하게 진행되며 경부암의 원인으로도 작용하는 것으로 보고되어 있다(Melnick, J. L., Adam, E. and Rawls, W., Concer, 34, 1355-1385, 1974). 또한, 신생아나 태아의 경우에는 스스로 HSV 항체를 생성하지 못할 뿐 아니라 모체의 항체가 태아에게 넘어가지 못하기 때문에, 일단 감염되면 대부분 치명적인 결과를 초래하게 된다고 알려져 있다. 현재, HSV-1에 의한 안구질환의 경우는 미국 내에서만 1년에 약 50만 명의 환자가 발생하며 이중 1000명 이상은 안구 이식수술을 받고 있는 것으로 알려져 있다. HSV-2의 경우 약 95%는 활동성 병변이 있는 상대방과의 성적 접촉을 통해 감염되는 것으로 알려져 있는데, 미국 성인 중 약 20~30%가 HSV-2에 감염되어 있으며, 이중 20 내지 50%는 재발성 성기 포진을 갖는 것으로 보고되어 있다(Johnson R. E. et al., N. Engl. J. Med., 321, 7,1989). Herpes Simplex Virus (hereinafter referred to as HSV) is a relatively large virus having a size of about 175 nm as a DNA virus belonging to the genus Herpesvirus, and is an infectious agent widely spread to humans. Herpes simplex infection is an infectious disease of HSV type 1 (hereinafter referred to as 'HSV-1') and HSV type 2 (hereinafter referred to as 'HSV-2'), It is a common infectious disease in people with HSV-1 mainly forms around the mouth and eye, and HSV-2 forms blisters around the penis. In addition, it has been reported that HSV infection is a serious cause of cervical cancer in immunocompromised patients (Melnick, JL, Adam, E. and Rawls, W., Concer, 1355-1385, 1974). In addition, it is known that newborns and fetuses can not produce HSV antibodies themselves, and that antibodies to maternal antibodies can not be passed on to the fetus. Currently, about 500,000 cases of HSV-1-associated ocular disease occur in the United States alone in a year, of which more than 1,000 are known to undergo eye transplant surgery. Approximately 95% of HSV-2 infections are known to be transmitted through sexual contact with opponents with active lesions. About 20% to 30% of US adults are infected with HSV-2, of which 20 to 50% (Johnson RE et al., N. Engl. J. Med., 321, 7, 1989).
HSV는 초기 감염 후에 피부나 점막 표피세포에서 복제를 시작하여 신경조직을 따라 이동한 후, 전 생애에 걸쳐 척추 신경절에 잠복하고 있다가 면역기능이 저하될 경우 재활성화되어 감염부위로부터 여러 가지 질환을 발생시키는 것으로 알려져 있다. HSV에 의한 감염질환에 대한 치료제로는 뉴클레오사이드(nucleoside) 유도체인 아시클로비르(Acyclovir)가 초기감염에 매우 효과적인 것으로 알려져 있으나(Bryson, Y. J. et al., N. Engl. J. Med., 308, 916, 1983), 이 약제의 효과를 유지하기 위해서는 약제를 계속해서 투여해야 하며, 투여가 중단될 경우 HSV에 의한 감염질환이 재발하는 것으로 알려져 있다(Mindel A. et al., Lancet i: 926-928(1988); Straus S.E. et al., N. Engl. J. Med., 310, 1545(1984)). 또한 HSV의 최초 감염에 대한 치료 후 재발하는 경우에는 치사율이 높다고 보고되어 있다(Nahmias, A. J. and Coleman, R. M., Immunobiology of Herpes Simplex Virus Infection CRC Press, Boca Raton, 92-102,1984).After HSV infection, HSV begins to replicate in skin or mucosal epidermal cells and travels along the nervous system. After HSV infection, HSV is latent in the spinal ganglia throughout the entire life span, and reactivates when the immune function deteriorates. ≪ / RTI > Acyclovir, a nucleoside derivative, is known to be highly effective for early infections (Bryson, YJ et al., N. Engl. J. Med. 308, 916, 1983). In order to maintain the efficacy of this drug, it is necessary to continuously administer the drug, and when the administration is discontinued, the infectious disease caused by HSV recurs (Mindel A. et al., Lancet i: Straus SE et al., N. Engl. J. Med., 310, 1545 (1984)). It has also been reported that recurrence after treatment for the first infection of HSV has a high mortality (Nahmias, A.J. and Coleman, R.M., Immunobiology of Herpes Simplex Virus Infection CRC Press, Boca Raton, 92-102,1984).
지금까지 이러한 HSV의 감염을 예방하기 위한 백신이 개발되어 왔으나, 바이러스 자체를 약화시켜 사용하는 생백신(live attenuated vaccine)은 HSV의 게놈이 종양발생(oncogenesis)에 직접 관여한다는 사실이 밝혀짐으로 인해서 그 사용이 금지되어 왔다(Cappel, R., Sprecher, S., De Cuyper, F. and De Braekeleer, J., J. Med. Virol., 16, 137-145,1985).Although a vaccine has been developed to prevent the infection of HSV, live attenuated vaccine, which weakens the virus itself, has been shown to be directly involved in the oncogenesis of the HSV genome. (Cappel, R., Sprecher, S., De Cuyper, F. and De Braekeleer, J., J. Med. Virol., 16, 137-145, 1985).
이러한 상황하에서, 최근 해외 및 국내에서 기존의 항바이러스 제제의 단점을 극복하고자 하는 많은 노력들이 이루어지고 있으며, 그 중의 하나로 국내에서는 생약 추출물 및 식물 추출물을 대상으로 항바이러스 효능에 대한 연구가 진행중이기는 하지만, 아직까지는 미비한 실정이므로, 기존의 항바이러스 제제의 단점을 극복하여 독성 및 부작용이 거의 없이 우수한 선천면역 증진 효과 및 항바이러스 활성을 발휘할 수 있는 생약 추출물을 유효성분으로 하는 조성물의 개발이 필요한 실정이다.Under these circumstances, many efforts have recently been made to overcome the disadvantages of existing antiviral agents both at home and abroad. One of them is research on the antiviral efficacy of herbal medicine extracts and plant extracts in Korea , It is necessary to develop a composition containing the herbal medicine extract as an active ingredient which can overcome the disadvantages of the existing antiviral agent and exhibit the innate immune enhancing effect and the antiviral activity with almost no toxicity and side effects .
한편, 자완(Asteris Radix)은 개미취(Aster tataricus L.)의 뿌리로 각지의 산과 들, 강기슭, 풀밭에서 널리 자라며 꽃보기식물 또는 약초로 심기도 한다. 자원, 소판, 협판채, 산백채, 자완, 자와라고도 한다. 깊은 산속 습지에서 자생하나 재배하기도 한다. 높이는 야생이 1.5m 정도이고 재배하는 것은 약 2m이다. 트리테르페노이드인 프리델린, 에피프리델린, 시오논, 결정성 사포닌, 쿠마린 화합물인 아우랍텐과 그 유도체 쿠에르세틴 등이 함유되어 있다(문관심, 약초의 성분과 이용, p718, 1984).On the other hand, Asteris Radix is a root of Aster tataricus L. It grows widely in mountains, fields, rivers and grasses of various places and is planted with flower viewing plants or herbs. It is said to be resource, plagiarism, chalkboard, mountain white, jawan, zawah. It grows wild in deep marsh wetlands and grows. The height is about 1.5m in the wild and about 2m in height. Triterpenoids such as pretilin, epiphedrine, sionone, crystalline saponins, coumarin compounds au lapten and derivatives thereof, quercetin, etc. (Moon, interest, herbal composition and utilization, p. 718, 1984).
약리효과로는 거담, 진해, 항균, 항암작용이 있다고 보고되어 있다. 자완의 성분 연구에 의하면, 그 뿌리에는 에피프리델리놀(epifriedelinol), 프리델린(friedelin), 시오논(shionone), 애스터사포닌(astersaponin)과 케르세틴(quercetine)이 들어 있고, 정유 중에는 라크노필롤(lachnophyllol), 라크노필롤 아세테이트(lachnophyllol acetate), 애니톨(anethole)과 지방산 등이 함유되어 있는 것으로 알려져 있다(강소신의학원편. 중약대사전. 서울 : 1998:4625-30). 또한, 한국공개특허 제2004-0065498호에 알러지성 피부염 및 피부 가려움 완화 효과를 갖는 천연조성물로 개시되어 있고, 한국등록특허 제0516194호에 항종양 활성을 갖는 생약 추출물에 관해 개시되어 있으며, 한국공개특허 제2012-0117115호에 자완 추출물을 함유하는 모발 성장 촉진 또는 탈모 방지용 조성물에 관해 개시되어 있다. 하지만 아직까지는 자완 추출물을 이용한 선천면역 증진 효과 및 항바이러스 활성에 관해 보고된 바 없다. The pharmacological effects are reported to be gadam, shinhae, antibacterial and anticancer effects. According to Javan's ingredient research, its roots contain epifriedelinol, friedelin, shionone, astersaponin and quercetine, and in the oil, (lachnophyllol), lachnophyllol acetate, anethole, and fatty acids (Jangsoo Shin, Institute of Chinese Medicine, Seoul: 1998: 4625-30). Korean Patent Publication No. 2004-0065498 discloses a natural composition having an allergic dermatitis and a skin itching relieving effect, discloses a herbal medicine extract having antitumor activity in Korean Patent No. 0516194, Japanese Patent Application Laid-Open Publication No. 2001-0117115 discloses a composition for promoting hair growth or preventing hair loss, which contains Haechin extract. However, there has been no report on congenital immunity enhancement and antiviral activity using the extract of Zaanxi.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 자완 추출물이 선천 면역의 주요 세포인 대식 세포를 활성화시켜 다양한 바이러스의 증식을 억제할 수 있음을 확인함으로써 본 발명을 완성하였다. 또한, 본 발명은 독성 및 부작용이 거의 없어 장기간 안전성을 확보하면서, 각종 바이러스 또는 세균에 의한 감염성 질환의 예방 또는 치료용 약학 조성물, 건강기능식품 또는 가축 사료 조성물 등에 효과적으로 이용될 수 있는 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스 조성물, 동물의 선천면역 증진 및 항바이러스 활성 증진 방법을 제공하는 것을 목적으로 한다.Accordingly, the present invention has been accomplished on the basis of these findings. It is an object of the present invention to provide a method for inhibiting the growth of various viruses by activating macrophages, the main cells of innate immunity. The present invention also provides a method for the prevention and treatment of infectious diseases caused by various viruses or germs, which is effective for long-term safety with little toxicity and side effects, And a method for promoting innate immunity and antiviral activity of an animal.
상기 목적을 달성하기 위하여, 본 발명은 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 약학 조성물을 제공한다.In order to accomplish the above object, the present invention provides a concomitant immunity enhancing and antiviral pharmaceutical composition comprising an extract of Zyklon as an active ingredient.
또한, 본 발명은 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 건강기능식품을 제공한다.In addition, the present invention provides a congenital immunity-enhancing and antiviral health functional food comprising an extract of Zyklon as an active ingredient.
또한, 본 발명은 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 사료 조성물을 제공한다.In addition, the present invention provides a congenital immunity enhancing and antiviral feed composition comprising an extract of Jiaxiang as an active ingredient.
또한, 본 발명은 인간을 제외한 선천면역 증진이 필요한 동물에 자완 추출물을 투여하는 것을 특징으로 하는 동물의 선천면역 증진 및 항바이러스 활성의 증진 방법을 제공한다. In addition, the present invention provides a method for enhancing innate immunity and antiviral activity of an animal, which comprises administering a helminthic extract to an animal requiring innate immune enhancement except for a human.
본 발명에 따르면 우수한 선천면역 증진 효능을 발휘하는 자완 추출물을 이용함으로써 각종 바이러스 및 세균 감염성 질병의 예방 및 치료에 효과적으로 적용될 수 있으며, 면역력 증진에 기여할 수 있다.According to the present invention, it is possible to effectively apply to the prevention and treatment of various viruses and bacterial infectious diseases by using a human-derived extract that exhibits excellent innate immune enhancing effect, and can contribute to enhancement of immunity.
또한, 본 발명에 따른 자완 추출물을 포함하는 선천면역 증진 및 항바이러스용 조성물은 독성이나 부작용을 거의 일으키지 않으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다. 따라서 본 발명에 따른 조성물은 박테리아 및 바이러스에 의한 감염성 질환의 예방 및 치료용으로 적용될 수 있고, 면역이 저하되거나 면역이 억제된 환자의 면역력 증진 및 조절을 위한 약학 조성물이나 건강기능식품, 및 동물의 항 질병 강화를 목적으로 하는 면역증진용 사료 조성물 등으로 광범위하게 이용될 수 있다.In addition, since the composition for congenital immunity enhancement and antiviral containing the human milk extract according to the present invention hardly causes toxicity or side effects, it can be safely used for prophylactic purposes for a long time. Accordingly, the composition according to the present invention can be applied for the prevention and treatment of infectious diseases caused by bacteria and viruses, and can be applied to pharmaceutical compositions and health functional foods for immunity enhancement and control of immunocompromised patients, And an immunity enhancing feed composition aimed at enhancing anti-disease.
또한, 본 발명에 따르면 자완 추출물을 선천면역 증진에 필요한 동물에 투여함으로써 동물의 면역을 효과적으로 안전하게 증진시킬 수 있다.In addition, according to the present invention, the immunization of an animal can be effectively and safely promoted by administering the extract of Zykllauchia sinensis to an animal necessary for congenital immunity enhancement.
도 1은 본 발명의 일 실시예에 따른 자완 추출물의 인플루엔자바이러스(PR8-GFP virus)에 대한 항바이러스 활성분석 결과이다. Medium은 음성 대조군으로 아무것도 처리하지 않은 세포군; PR8-GFP는 바이러스 감염군; IFN-β/PR8-GFP는 양성대조군으로, PR8-GFP 바이러스 감염 및 1,000Units/㎖의 IFN-β 처리군; 자완/PR8-GFP는 PR8-GFP 바이러스 감염 및 자완 추출물 처리군이다.
도 2는 본 발명의 일 실시예에 따른 자완 추출물의 수포성구내염바이러스(VSV-GFP virus)에 대한 항바이러스 활성분석 결과이다. Medium은 음성 대조군으로 아무것도 처리하지 않은 세포군; VSV-GFP는 바이러스 감염군; IFN-β/VSV-GFP는 양성대조군으로, VSV-GFP 바이러스 감염 및 1,000Units/㎖의 IFN-β 처리군; 자완/VSV-GFP는 VSV-GFP 바이러스 감염 및 자완 추출물 처리군이다.
도 3은 본 발명의 일 실시예에 따른 자완 추출물의 단순포진바이러스(HSV-GFP virus)에 대한 항바이러스 활성분석 결과이다. Medium은 음성 대조군으로 아무것도 처리하지 않은 세포군; HSV-GFP는 바이러스 감염군; IFN-β/HSV-GFP는 양성대조군으로, HSV-GFP 바이러스 감염 및 1,000Units/㎖의 IFN-β 처리군; 자완/HSV-GFP는 HSV-GFP 바이러스 감염 및 자완 추출물 처리군이다.
도 4는 본 발명의 일 실시예에 따른 자완 추출물의 뉴캐슬병바이러스(NDV-GFP virus)에 대한 항바이러스 활성분석 결과이다. Medium은 음성 대조군으로 아무것도 처리하지 않은 세포군; NDV-GFP는 바이러스 감염군; IFN-β/NDV-GFP는 양성대조군으로, NDV-GFP 바이러스 감염 및 1,000Units/㎖의 IFN-β 처리군; 자완/NDV-GFP는 NDV-GFP 바이러스 감염 및 자완 추출물 처리군이다.
도 5는 본 발명의 일 실시예에 따른 자완 추출물의 엔테로바이러스(EV-71 virus)에 대한 항바이러스 활성분석 결과이다. Medium은 음성 대조군으로 아무것도 처리하지 않은 세포군; EV-71는 바이러스 감염군; IFN-β/EV-71은 양성대조군으로, EV-71 바이러스 감염 및 1,000Units/㎖의 IFN-β 처리군; 자완/EV-71는 EV-71 바이러스 감염 및 자완 추출물 처리군이다.
도 6은 본 발명의 실시예에 따른 자완 추출물에 의한 전 염증성 사이토카인 유도 분석결과이다.
도 7은 본 발명의 일 실시예에 따른 자완 추출물을 Raw 264.7 세포에 처리하여 항바이러스 유전자 중에서 IFN-β, PKR(Protein Kinase R), PML(promyelocytic leukemia), GBP1(Guanylate binding protein 1), OAS(2'-5'-oligoadenylate synthetase 1), Interferon-induced GTP-binding protein Mx1, ISG56(Interferon-stimulated gene 56), ISG20(Interferon-stimulated gene 20) 및 ISG15(Interferon-stimulated gene 15)의 mRNA 발현 유도를 확인한 결과이다.
도 8은 본 발명의 일 실시예에 따른 자완 추출물의 면역관련 신호전달 분자들의 활성화 유도를 확인한 결과이다.
도 9는 본 발명의 실시예에 따른 자완 추출물에 의한 인플루엔자바이러스(H1N1 및 H5N2)의 감염 억제를 확인한 결과이다. H1N1 및 H5N2는 인플루엔자바이러스만 처리(1.0 MOI)된 군이고, Medium은 음성대조군으로 아무것도 처리되지 않은 MDCK 세포군이며, 자완/H1N1 및 자완/H5N2는 자완 추출물과 인플루엔자바이러스(1.0 MOI)를 동시에 처리한 군이다.
도 10은 본 발명의 일 실시예에 따른 자완 추출물의 처리에 따른 H1N1 바이러스 감염 동물 모델의 생존률(%)을 나타낸 결과이다. 1 is a graph showing the results of analysis of antiviral activity against influenza virus (PR8-GFP virus) of the human milk extract according to one embodiment of the present invention. Medium is a negative control group of cells that have not been treated; PR8-GFP is a group of virus infections; IFN-? / PR8-GFP as a positive control, PR8-GFP virus infection and 1,000 units / ml IFN-? Treatment group; Jawan / PR8-GFP is a group treated with PR8-GFP virus infection and human-derived extract.
FIG. 2 shows the results of analysis of antiviral activity against virus-like stomatitis virus (VSV-GFP virus) of the human milk extract according to one embodiment of the present invention. Medium is a negative control group of cells that have not been treated; VSV-GFP is a virus-infected group; IFN-β / VSV-GFP was a positive control group, with VSV-GFP virus infection and 1,000 units / ml IFN-β treatment group; Jawan / VSV-GFP is a group treated with VSV-GFP virus infection and human milk extract.
FIG. 3 shows the results of analysis of antiviral activity against herpes simplex virus (HSV-GFP virus) of the human milk extract according to one embodiment of the present invention. Medium is a negative control group of cells that have not been treated; HSV-GFP is a virus-infected group; IFN-β / HSV-GFP as a positive control, HSV-GFP virus infection and 1,000 units / ml IFN-β treatment group; Jawan / HSV-GFP is a group of HSV-GFP viral infections and a self-help extract.
FIG. 4 is a graph showing the results of antiviral activity assay for the Newcastle disease virus (NDV-GFP virus) of the present invention of the present invention. Medium is a negative control group of cells that have not been treated; NDV-GFP is a virus-infected group; IFN-? / NDV-GFP is a positive control group, NDV-GFP virus infection and 1,000 units / ml IFN-? Treatment group; Jawan / NDV-GFP is a group treated with NDV-GFP virus infection and human milk extract.
FIG. 5 is a graph showing the results of antiviral activity analysis of enterobacteriaceae (EV-71 virus) according to one embodiment of the present invention. Medium is a negative control group of cells that have not been treated; EV-71 is a virus-infected group; IFN-beta / EV-71 was a positive control group, with EV-71 viral infection and 1,000 Units / ml IFN-? Treatment group; Jawan / EV-71 is a group treated with EV-71 viral infection and human milk extract.
FIG. 6 is a graph showing the results of proinflammatory cytokine induction assay by the human milk extract according to the embodiment of the present invention.
FIG. 7 is a graph showing the results of treatment of Raw 264.7 cells according to an embodiment of the present invention by treating IFN-β, PKR (protein kinase R), PML (promyelocytic leukemia), GBP1 (guanylate binding protein 1) (2'-5'-oligoadenylate synthetase 1), mRNA expression of interferon-induced GTP-binding protein Mx1, ISG56 (interferon-stimulated gene 56), ISG20 (interferon-stimulated gene 20) and ISG15 Induction is the result of confirmation.
8 is a result of confirming the induction of activation of immune-related signal transduction molecules of the extract of Zygawa according to an embodiment of the present invention.
FIG. 9 shows the results of confirming the inhibition of influenza virus (H1N1 and H5N2) infection by the human milk extract according to the embodiment of the present invention. H1N1 and H5N2 were treated with influenza virus only (1.0 MOI), Medium was negative control MDCK cell group, and Zawan / H1N1 and Hawan / H5N2 were treated simultaneously with AHWA and influenza virus (1.0 MOI) It is the county.
FIG. 10 shows the survival rate (%) of an H1N1 virus-infected animal model according to the present invention.
본 발명은 자완 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 약학 조성물에 관한 것이다. The present invention relates to a concomitant immunoconjugate and antiviral pharmaceutical composition comprising an extract of Zykllaus japonica as an active ingredient.
상기 자완 추출물은 물, 탄소수 1 내지 4의 알코올 중에서 선택된 1종 이상의 용매로 추출하는 것이 바람직하고, 더 바람직하게는 물, 메탄올, 에탄올, 또는 부탄올의 용매를 이용하여 추출하는 것이며, 더욱더 바람직하게는 물을 용매로 이용하여 열수 추출한 것이다. 상기 열수 추출은 1) 자완 중량을 기준으로, 5 내지 30배의 증류수를 첨가하는 단계; 2) 100~130℃의 온도에서 2~5시간 동안 열수 추출하는 단계; 및 3) 상기 열수 추출물을 여과하는 단계;를 거쳐 수행하는 것이 바람직하지만 이에 한정하지 않는다.Preferably, the extract is extracted with one or more solvents selected from water and alcohols having 1 to 4 carbon atoms, more preferably extracted with a solvent such as water, methanol, ethanol, or butanol, And extracted with hot water using water as a solvent. The hot water extraction comprises the steps of: 1) adding 5 to 30 times of distilled water based on the self-weight; 2) hot water extraction at a temperature of 100 to 130 ° C for 2 to 5 hours; And 3) filtering the hot-water extract. However, the present invention is not limited thereto.
또한, 상기 자완 추출물은 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 조정제물 또는 정제물 중 어느 하나를 포함하는 것으로 한다.In addition, the above-mentioned Zygwanaceous extract includes any one of an extract obtained by extraction treatment, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, or a preparation or a purified product.
본 발명의 자완 추출물이 항바이러스 활성을 갖는 바이러스의 일례는 오르토믹소비리대(Orthomixoviridae), 랍도비리대(Rhabdoviridae), 파라믹소비리대(Paramixoviridae), 허피스비리대(Herpesviridae) 및 피코나비리대(Picornaviridae) 중에서 선택된 하나 이상의 바이러스이며, 바람직하게는 인플루엔자바이러스, 뉴캐슬병바이러스, 수포성구내염바이러스(Vesicular stomatitis virus), 콕사키바이러스(Cossackie virus), 엔테로바이러스 71형(Enterovirus-71), 단순포진바이러스(Herpes Simplex Virus), 리노바이러스(Rhinovirus), 호흡기세포융합바이러스(respiratory syncytial virus; RSV), 구제역바이러스(Foot and mouth disease virus), 콜로라도참진드기열바이러스, 레오바이러스, 인간면역 결핍 바이러스, B형 간염바이러스, C형 간염바이러스, 돼지열병바이러스, 소바이러스성설사바이러스(Bovine Viral Diarrhea Virus), 돼지생식기호흡기증후군바이러스(Porcine reproductive and respiratory syndrome virus), 돼지오제스키병바이러스, 로타바이러스, 파보바이러스, 돼지유행성설사바이러스(Porcine epidemic diarrhea virus) 등이 있으며, 더 바람직한 바이러스의 일례는 인플루엔자바이러스, 뉴캐슬병바이러스, 수포성구내염바이러스, 단순포진바이러스, 엔테로바이러스 71형, 리노바이러스(Rhinovirus), 호흡기세포융합바이러스(respiratory syncytial virus; RSV)이지만 이에 제한하지 않는다.Examples of viruses having the antiviral activity of the human milk extract of the present invention include Orthomixoviridae, Rhabdoviridae, Paramixoviridae, Herpesviridae and Piconaviridae, (Picornaviridae), and preferably one or more viruses selected from the group consisting of influenza virus, Newcastle disease virus, Vesicular stomatitis virus, Cossackie virus, Enterovirus-71, Herpes simplex virus, rhinovirus, respiratory syncytial virus (RSV), foot and mouth disease virus, Colorado tick fever virus, reovirus, human immunodeficiency virus, B type Hepatitis virus, hepatitis C virus, swine fever virus, bovine viral diarrhea virus, Porcine reproductive and respiratory syndrome virus, porcine Ozeki disease virus, rotavirus, parvovirus, porcine epidemic diarrhea virus, and the like. Among the more preferable viruses are influenza virus, Newcastle disease virus , Vesicular stomatitis virus, herpes simplex virus,
본 발명의 자완 추출물은 면역 인자 유도능을 강하게 나타내며, 개체의 선천면역을 증가시켜 바이러스의 감염 및 증식을 억제하는 효과가 있을 뿐만 아니라, 세포 독성이나 부작용을 거의 나타내지 않으므로 장기간 복용시에도 안심하고 사용할 수 있는 것을 특징으로 한다. 병원체의 감염 시 선천 면역의 방어 기작의 하나로 면역 인자가 분비되는데, 이들 면역 인자들(TNF-α, IL-6 및 IFN-β)의 분비가 병원체를 방어하므로, 적정한 수준의 사이토카인의 반응 유도는 다양한 전염병 병원체에 대한 예방 및 치료 방법이 될 수 있다. 특히 바이러스에 대한 면역력을 증강시킬 수 있는 것이다. The present invention relates to a method for the treatment and prevention of infection and proliferation of viral infections. The method of the present invention is characterized in that the vaccine extract of the present invention strongly induces an immune factor-inducing ability and increases innate immunity of an individual to inhibit infection and proliferation of viruses. . The secretion of these immune factors (TNF-α, IL-6, and IFN-β) protects the pathogen, so that the appropriate level of cytokine induction Can be a preventive and therapeutic method for various infectious pathogens. In particular, it can strengthen the immunity against viruses.
본 발명의 선천면역 증진 및 항바이러스용 약학 조성물은 약학적으로 허용가능한 담체, 부형제 또는 희석제를 더 포함할 수 있다. 본 발명에 이용될 수 있는 약학적으로 허용가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 특별히 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다. 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다. 본 발명의 선천면역 증진 및 항바이러스용 약학 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁액, 에멀젼, 시럽제, 에어로졸, 외용제, 좌제 및 주사제로 이루어진 군으로부터 선택되는 형태일 수 있다. 약학 조성물의 제제화 방법은 기술분야에 공지된 통상의 방법에 따라 수행될 수 있으며, 특별히 제한되지 않는다. The pharmaceutical composition for congenital immunity enhancement and antiviral of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent. The pharmaceutically acceptable carrier, excipient or diluent which can be used in the present invention is not particularly limited so long as the effect of the present invention is not impaired. For example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, Flavoring agents, fragrances, preservatives, and the like. Representative examples of pharmaceutically acceptable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium carbonate, calcium Methylcellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable Ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper. The pharmaceutical composition for congenital immunity enhancement and antiviral of the present invention may be in the form of a tablet, a pill, a powder, a granule, a capsule, a suspension, an emulsion, a syrup, an aerosol, a external preparation, a suppository and an injection. The method of preparing the pharmaceutical composition may be performed according to a conventional method known in the art, and is not particularly limited.
본 발명의 선천면역 증진 및 항바이러스용 약학 조성물은 경구 또는 비경구 투여될 수 있으며, 투여량은 투여 대상의 연령, 성별, 체중, 상태, 질병의 정도, 약물의 형태, 투여 경로 및 기간에 따라 적절히 선택될 수 있으나, 일반적으로 약 5~500㎎/㎏, 바람직하게는 약 100~250㎎/㎏을 1일 1~3회 투여할 수 있다.The pharmaceutical composition for congenital immunity enhancement and antiviral use according to the present invention may be administered orally or parenterally. The dosage may be adjusted according to the age, sex, weight, condition, degree of disease, drug form, May be appropriately selected, but generally about 5 to 500 mg / kg, preferably about 100 to 250 mg / kg, can be administered one to three times a day.
본 발명의 선천면역 증진 및 항바이러스용 약학 조성물의 제제화 방법, 투여량, 투여 경로, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다. It will be apparent to those skilled in the art that the method of concomitant immunization enhancement and formulation of pharmaceutical compositions for antiviral use of the present invention, dosage, route of administration, constituents, etc., can be appropriately selected from conventional techniques known in the art.
본 발명의 선천면역 증진 및 항바이러스용 약학 조성물은 박테리아 감염성 질병 또는 바이러스 감염성 질병의 예방 및 치료에 이용될 수 있다. 본 발명의 선천면역 증진 및 항바이러스용 약학 조성물은 유효 성분으로 자완 추출물 외에 다른 약학적 활성 성분을 함께 포함하거나, 또는 다른 유효 성분을 포함하는 약학 조성물과 혼합되어 이용될 수 있다. The congenital immunity enhancing and antiviral pharmaceutical compositions of the present invention can be used for the prevention and treatment of bacterial infectious diseases or viral infectious diseases. The pharmaceutical composition for congenital immunity enhancement and antiviral use according to the present invention may be used as an active ingredient in combination with a pharmaceutical composition containing other active ingredients in addition to the composition of the present invention.
또한, 본 발명은 자완 추출물을 포함하는 선천면역 증진 및 항바이러스용 건강기능식품에 관한 것이다. 본 발명의 선천면역 증진 및 항바이러스용 건강기능식품은 식품학적으로 허용가능한 식품 보조 첨가제를 더 포함할 수 있다. 본 발명에 이용될 수 있는 식품학적으로 허용가능한 식품 보조 첨가제는 포도당, 과당, 말토오스, 슈크로스, 덱스트린, 시클로덱스트린과 같은 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올과 같은 천연 탄수화물, 타우마틴, 스테비아 추출물 등의 천연 향미제, 사카린, 아스파르탐산 등의 합성 향미제, 착색제, 펙트산 또는 그의 염, 알긴산 또는 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산화제 등을 포함하나, 이에 제한되는 것은 아니다. 본 발명의 선천면역 증진 및 항바이러스용 건강기능식품은 분말, 과립, 정제, 캡슐, 캔디, 츄잉검, 젤리 및 음료로 이루어진 군으로부터 선택되는 형태일 수 있다. 선천면역 증진 및 항바이러스용 건강기능식품 중의 자완 추출물의 함량은 식품의 형태, 풍미, 맛 등을 고려하여 적절하게 선택될 수 있으며, 예를 들어 건강기능식품 전체 중량에 대하여 0.01~30 중량%의 범위일 수 있다. 본 발명의 선천면역 증진 및 항바이러스용 건강기능식품의 형태, 조성 및 제조방법 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다.In addition, the present invention relates to a health functional food for congenital immunity enhancement and antiviral treatment comprising an extract of Zygomai. The congenital immunity enhancing and antiviral health functional food of the present invention may further include a food acceptable food supplementary additive. Food-acceptable food supplementary additives that may be used in the present invention include sugars such as glucose, fructose, maltose, sucrose, dextrin, cyclodextrins, natural carbohydrates such as sugar alcohols such as xylitol, sorbitol and erythritol, , Natural flavor such as stevia extract, synthetic flavor such as saccharin and aspartame, colorant, pectic acid or its salt, alginic acid or its salt, organic acid, protective colloid thickener, pH adjusting agent, Alcohols, carbonates, and the like. The congenital immunity enhancing and antiviral health functional food of the present invention may be in a form selected from the group consisting of powder, granule, tablet, capsule, candy, chewing gum, jelly and beverage. The content of the human milk extract in the healthy functional food for convalescent immunization and antiviral can be appropriately selected in consideration of the shape, flavor, taste, etc. of the food, and for example, 0.01 to 30% by weight Lt; / RTI > It is apparent to those of ordinary skill in the art that the form, composition and manufacturing method of the health functional food for congenital immunity enhancement and antiviral of the present invention can be appropriately selected from conventional techniques known in the art.
또한, 본 발명은 자완 추출물을 포함하는 선천면역 증진 및 항바이러스용 사료 조성물에 관한 것이다. 선천면역 증진 및 항바이러스용 사료 조성물 중의 자완 추출물의 함량은 급여 가축의 종, 주령, 체중, 및 사육 조건 등에 따라 적절히 선택될 수 있으며, 사료 조성물 전체 중량에 대하여 0.01~95중량%, 바람직하게는 0.1~80중량%의 비율일 수 있다. 본 발명의 선천면역 증진 및 항바이러스용 사료 조성물은 기술분야에 공지된 사료 제조방법에 따라 제조될 수 있으며, 예를 들어, 각종 사료 원료 또는 배합사료와 본 발명의 자완 추출물을 혼합한 후, 추가적인 가공 공정, 예를 들어 펠렛 형태로의 성형 또는 과립 등의 형태로의 절단 단계 등을 더 수행함으로써 제조될 수 있다. 본 발명의 선천면역 증진 및 항바이러스용 사료 조성물의 구성성분, 조성, 제조방법, 급여방법 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다. In addition, the present invention relates to a congenital immunity enhancing and antiviral feed composition comprising a chrysanthemum extract. The content of the human milk extract in the feed composition for congenital immunity enhancement and antiviral treatment can be appropriately selected according to the species, age, body weight, rearing condition and the like of the feed livestock, and is 0.01 to 95% by weight, 0.1 to 80% by weight. The congenital immunity enhancing and antiviral feed composition of the present invention can be prepared according to a feed production method known in the art. For example, after mixing various feed materials or compound feeds with the present invention's herbal extract, For example, a step in the form of a pellet or a step in the form of granules or the like. It is apparent to those skilled in the art that the composition, composition, manufacturing method, feeding method, and the like of the congenital immunity enhancing and antiviral feed composition of the present invention can be appropriately selected from conventional techniques known in the art.
또한, 본 발명은 인간을 제외한 선천면역 증진이 필요한 동물에 자완 추출물을 투여하는 것을 특징으로 하는 동물의 선천면역 증진 및 항바이러스 활성의 증진 방법에 관한 것이다. 본 발명의 동물의 선천면역 증진 및 항바이러스 활성 증진에 있어서, 자완 추출물의 투여량, 투여경로, 투여 시기 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다.
The present invention also relates to a method for enhancing innate immunity and antiviral activity of an animal, which comprises administering a helminth-like extract to an animal that requires congenital immunity enhancement except for a human. It is apparent to those skilled in the art that the dose, route of administration, administration time, etc. of the human milk extract may be appropriately selected from conventional techniques known in the art in enhancing innate immunity and antiviral activity of the animal of the present invention .
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.
실시예Example 1. 자완 추출물의 제조 1. Manufacture of human milk extract
자완 추출물은 자완의 중량을 기준으로, 20배의 증류수를 자완에 첨가하여 115℃에서 180분간 열수 추출하고, 0.45㎛로 1차 여과한 후, 0.22㎛로 2차 여과하여 침전물을 제거하였다. 이어서, pH를 7.0으로 조정하여 1.5㎖ Ep-튜브에 1㎖씩 분주하고 -20℃에서 저장하여 모든 분석에 사용하였다.
The extract of Haean was extracted by hot water extraction at 115 ℃ for 180 min, primary filtration at 0.45 ㎛ and secondary filtration at 0.22 ㎛ to remove precipitate. Subsequently, the pH was adjusted to 7.0, and 1 ml of each was dispensed into a 1.5 ml Ep-tube and stored at -20 캜 for use in all analyzes.
실시예Example 2. 자완 추출물의 항바이러스 활성 분석 2. Antiviral activity analysis of human milk extract
인플루엔자바이러스(Influenza virus; PR8), 수포성구내염바이러스(Vesicular stomatitis virus), 단순포진바이러스(Herpes simplex virus; HSV), 뉴캐슬병바이러스(Newcastle disease virus) 및 엔테로바이러스 71형(Enterovirus-71; EV-71)에 대한 자완 추출물의 항바이러스 활성 분석을 수행하였다.
Influenza virus (PR8), Vesicular stomatitis virus, Herpes simplex virus (HSV), Newcastle disease virus and enterovirus type 71 (Enterovirus-71; EV-71 ) Were analyzed for antiviral activity.
(1) 항바이러스 활성 분석 방법(1) Antiviral activity assay method
인플루엔자바이러스(Influenza virus; PR8), 수포성구내염바이러스(Vesicular stomatitis virus; VSV), 단순포진바이러스(HSV-GFP) 및 뉴캐슬병바이러스(Newcastle disease virus) 를 마우스 대식세포주인 Raw 264.7 세포(8×105cell/well)에 감염시켜 분석하였고, 엔테로바이러스 71형(Enterovirus-71; EV-71)은 Hela 세포에 감염시켜 분석하였다.Influenza virus (Influenza virus; PR8), vesicular stomatitis virus (Vesicular stomatitis virus; VSV), a Raw 264.7 cells (8 × 10 5 to herpes simplex virus (HSV-GFP) and Newcastle disease virus (Newcastle disease virus) mouse macrophage cell line (Enterovirus-71; EV-71) was infected with Hela cells and analyzed.
12-웰 TC 플레이트에 세포를 배양한 후, 1% FBS가 첨가된 DMEM에 상기 실시예 1에서 제조한 1㎍/㎖의 자완 추출물(pH 조정)을 각각 처리하였다. 음성 대조군은 1% FBS가 첨가된 DMEM만을 처리하였고, 양성 대조군(Positive control)은 마우스 IFN-β(500units/㎖)를 처리하였다. 자완 추출물의 처리 12시간 후, PR8-GFP(MOI:1.0), VSV-GFP(MOI:1.0), HSV-GFP(MOI:3.0), NDV-GFP(MOI:3.0) 및 EV-71(MOI:1.0)를 각각 접종하였다. 접종하고 2시간 후 접종액을 제거하고, PBS로 3회 세척하고, 12 및 24시간 후, 바이러스 감염 정도를 확인하였다.
Cells were cultured on a 12-well TC plate, and DMEM supplemented with 1% FBS was treated with 1 μg / ml of the human milk extract (pH adjusted) prepared in Example 1, respectively. Negative controls were treated with DMEM supplemented with 1% FBS, and positive controls were treated with mouse IFN-β (500 units / ml). GFP (MOI: 1.0), HSV-GFP (MOI: 3.0), NDV-GFP (MOI: 3.0) and EV-71 (MOI: 1.0), respectively. After 2 hours of inoculation, the inoculum was removed, washed three times with PBS, and after 12 and 24 hours, the degree of virus infection was confirmed.
(2) 항바이러스 활성 분석결과(2) Antiviral activity assay results
1) 인플루엔자바이러스(1) Influenza virus ( PR8PR8 -- GFPGFP virusvirus )의 분석결과) Analysis result
인플루엔자바이러스에 대한 항바이러스 활성 분석결과를 도 1에 개시하였다. 도 1(a)는 감염 12시간 후의 GFP(green fluorescent protein) 형광이미지를 나타내고, 도 1(b)는 감염 24시간 후의 GFP(green fluorescent protein) 형광이미지를 나타내며, 도 1(c)는 감염 12시간 및 24시간 후의 세포생존율을 나타내며, 도 1(d)는 세포 내에 존재하는 바이러스의 개수를 나타낸 것이다. 자완 추출물로 처리한 결과, 인플루엔자바이러스의 감염률이 현저하게 떨어졌으며, 세포 생존율도 바이러스 감염군에 비해 상승한 것을 확인할 수 있었다(도 1).
The results of analysis of antiviral activity against influenza virus are shown in Fig. 1 (a) shows GFP (green fluorescent protein) fluorescence image after 12 hours of infection, FIG. 1 (b) shows green fluorescent protein (GFP) fluorescence image after 24 hours of infection, And cell survival rate after 24 hours, and Fig. 1 (d) shows the number of viruses present in the cells. As a result, the infection rate of influenza virus was remarkably decreased and the cell survival rate was also higher than that of virus infection group (Fig. 1).
2) 2) 수포성구내염바이러스(VSV-GFP virus)의Of vesicular stomatitis virus (VSV-GFP virus) 분석결과 Analysis
수포성구내염바이러스에 대한 항바이러스 활성 분석 결과를 도 2에 개시하였다. 도 2(a)는 감염 12시간 후의 GFP(green fluorescent protein) 형광이미지를 나타내고, 도 2(b)는 감염 24시간 후의 GFP(green fluorescent protein) 형광이미지를 나타내며, 도 2(c)는 감염 12시간 및 24시간 후의 세포생존율을 나타내며, 도 2(d)는 세포 내에 존재하는 바이러스의 개수를 나타낸 것이다. 도 2로부터 확인할 수 있는 바와 같이, 자완 추출물로 처리한 결과, 수포성구내염바이러스의 감염률이 현저하게 떨어졌으며, 바이러스 역가도 감소하였고, 세포 생존율도 바이러스 감염군에 비해 상승하였다.
The results of antiviral activity assay for vesicular stomatitis virus are shown in Fig. FIG. 2 (a) shows GFP (green fluorescent protein) fluorescence image after 12 hours of infection, FIG. 2 (b) shows green fluorescent protein (GFP) fluorescence image after 24 hours of infection, And cell survival rate after 24 hours, and Fig. 2 (d) shows the number of viruses present in the cells. As can be seen from FIG. 2, as a result of treatment with Zygomma extract, the infection rate of vesicular stomatitis virus was remarkably decreased, the virus level was decreased, and the cell survival rate was also higher than that of virus infection group.
3) 단순포진바이러스(3) Herpes simplex virus ( HSVHSV -- GFPGFP virusvirus )의 분석결과) Analysis result
단순포진바이러스에 대한 항바이러스 활성 분석결과를 도 3에 개시하였다. 도 3(a)는 감염 12시간 후의 GFP 형광이미지를 나타내고, 도 3(b)는 감염 24시간 후의 GFP 형광이미지를 나타내며, 도 3(c)는 감염 12시간 및 24시간 후의 세포 생존율을 나타내며, 도 3(d)는 세포 내에 존재하는 바이러스의 개수를 나타낸 것이다. 도 3으로부터 확인할 수 있는 바와 같이, 자완 추출물로 처리한 결과, 단순포진바이러스의 감염률이 현저하게 떨어졌으며, 세포 생존율도 바이러스 감염군에 비해 상승하였다.
The results of analysis of antiviral activity against herpes simplex virus are shown in Fig. 3 (a) shows GFP fluorescence image after 12 hours of infection, FIG. 3 (b) shows GFP fluorescence image after 24 hours of infection, FIG. 3 (c) shows cell viability after 12 hours and 24 hours of infection, Figure 3 (d) shows the number of viruses present in the cells. As can be seen from FIG. 3, the infection rate of herpes simplex virus was significantly lowered and the cell survival rate was also higher than that of virus infection group.
4) 뉴캐슬병바이러스(NDV-GFP virus)의 분석결과 4 ) Analysis of Newcastle disease virus (NDV-GFP virus)
뉴캐슬병바이러스에 대한 항바이러스 활성 분석결과를 도 4에 개시하였다. 도 4(a)는 감염 24시간 후의 GFP 형광이미지를 나타내며, 도 4(b)는 상대적인 GFP 형광량을 나타낸 것이다. 도 4에 개시한 바와 같이, 뉴캐슬병바이러스가 감염된 세포에 자완 추출물을 처리한 결과, 뉴캐슬병바이러스가 현저하게 감소한 것을 확인하였다.
The results of antiviral activity assay for Newcastle disease virus are shown in FIG. Fig. 4 (a) shows GFP fluorescence image after 24 hours of infection, and Fig. 4 (b) shows the relative GFP type light amount. As shown in FIG. 4, when the cells infected with the Newcastle disease virus were treated with the self-extract, it was confirmed that the Newcastle disease virus was significantly reduced.
5) 5)
엔테로바이러스Enterovirus
((
EVEV
-71 -71
virusvirus
) 71형의 분석결과) Analysis result of
엔테로바이러스 71형에 대한 항바이러스 활성 분석결과를 도 5에 개시하였다. 도 5(a)는 감염 12시간 후의 광학이미지를 나타내고, 도 5(b)는 감염 24시간 후의 광학이미지를 나타내며, 도 5(c)는 엔테로바이러스 감염 24시간 후의 자완 추출물을 처리한 군에서 바이러스 복제가 감소하였다는 것을 나타낸 것이다. 도 5에 개시한 바와 같이, 엔테로바이러스 71형이 감염된 세포에 자완 추출물을 처리한 결과, 엔테로바이러스 71형이 현저하게 감소한 것을 확인하였다.
The results of antiviral activity assay for
실시예Example 3. 마우스 대식 세포주를 이용한 자완 3. Mouse embryonic stem cell line 의of 전 염증성 사이토카인 유도( Proinflammatory cytokine induction ( propro -- inflammatoryinflammatory CytokineCytokine InductionInduction ) 분석) analysis
자완 추출물의 면역인자 유도효과를 확인하기 위하여 전 염증성 사이토카인 유도 분석을 수행하였다.The proinflammatory cytokine induction assay was performed to confirm the induction of the immune factor induction of the chaebol extract.
(1) 전 염증성 사이토카인 유도 분석방법(1) proinflammatory cytokine induction assay method
마우스 대식세포주인 Raw 264.7을 키워 분석에 사용하였다. 6-웰 TC 플레이트에 세포를 배양한 후, 1% FBS가 첨가된 DMEM에 상기에서 제조된 자완 추출물(pH 조정)을 첨가하여 처리하였다. 음성 대조군은 1% FBS가 첨가된 DMEM만을 처리하였고, 양성 대조군은 바이러스, 암세포 등의 외부 물질에 반응하여 분비되는 사이토카인으로, 세포 내 항암 및 항바이러스 작용을 일으켜 면역반응을 유도하는 물질인 인터페론-β(IFN-β)를 1000Units/㎖ 처리하였다. 시료는 1㎍/㎖의 자완 추출물을 처리하고 12시간 후와 24시간 후의 세포에 대하여 TNF-α, IL-6 및 IFN-β의 생성량(pg/㎖)을 ELISA로 측정하였다.
Mouse macrophage line Raw 264.7 was used for the analysis. Cells were cultured on a 6-well TC plate and treated with DMEM supplemented with 1% FBS by addition of the above-prepared human milk extract (pH adjusted). The negative control group was treated with DMEM supplemented with 1% FBS, and the positive control group was a cytokine secreted in response to external substances such as viruses and cancer cells, and the interferon, which is an immune response inducing substance, -β (IFN-β) was treated at 1000 units / ml. The amount of TNF-α, IL-6 and IFN-β produced (pg / ml) was measured by ELISA for the cells treated with 1 μg / ml of human milk extract and after 12 hours and 24 hours.
(2) 전 염증성 사이토카인 유도 분석결과(2) Results of proinflammatory cytokine induction assay
자완 추출물에 의한 전 염증성 사이토카인 유도 분석결과를 도 6에 개시하였다. 종양괴사인자 알파(tumor necrosis factor-α; TNF-α)는 주로 활성화된 대식세포에 의해 분비되며, 가장 중요한 역할은 면역세포의 조절이다. 또한 바이러스 복제를 억제하는 능력이 있는 것으로 알려져 있다. 인터루킨 6(Interleukin 6; IL-6는 B-세포를 활성화시켜 항체생산을 증가시켜 항원특이적 면역반응을 촉진하는 중요한 사이토카인이다. 인터페론(Interferon; IFN)은 세포의 조절물질로서 그 기능이 아주 다양하다. 예를 들면, 바이러스로부터의 세포보호, 조직배양에서나 골수에서의 세포분열 억제, T세포의 작용 조절, 자연면역세포(NK세포)의 기능 항진을 유도하여 식균작용을 상승시키고, 특수 암세포의 분열 억제하는 것으로 알려져 있다.The results of the proinflammatory cytokine induction assay by the human milk extract are shown in Fig. Tumor necrosis factor-α (TNF-α) is mainly secreted by activated macrophages, the most important role being the regulation of immune cells. It is also known to have the ability to inhibit viral replication. Interleukin 6 (IL-6) is an important cytokine that stimulates B-cell activation and stimulates antigen-specific immune responses by increasing antibody production. Interferon (IFN) For example, cell protection from viruses, inhibition of cell division in bone marrow, suppression of T cell function, and hyperactivity of naturally-occurring immune cells (NK cells), thereby increasing phagocytosis, Which is known to inhibit the cleavage.
도 6에 개시한 바와 같이, Raw 264.7 세포에서 자완 추출물에 의해 전 염증성 사이토카인인 IL-6, TNF-α 및 IFN-β가 강하게 유도되는 것을 확인할 수 있다.
As shown in Fig. 6, it can be confirmed that the proinflammatory cytokines IL-6, TNF-a and IFN-? Are strongly induced by the human-derived extract in Raw 264.7 cells.
실시예Example 4. 4. 자완Wisdom 추출물의 처리에 따른 실시간 중합효소 연쇄반응( Real - Time Polymerase Chain Reaction with Extract Treatment realreal timetime PCR)을 이용한 항바이러스 유전자의 발현량 변화 분석 PCR) to analyze the expression level of antiviral gene
사이토카인 분비와 마찬가지로 면역관련 유전자들의 발현도 증가하는지를 확인하기 위하여 Raw264.7 세포주에 1%의 자완 추출물을 처리한 후, 12시간 후에 IFN-ß와 항바이러스 유전자의 발현량을 실시간 중합효소 연쇄반응(real time PCR)을 이용하여 측정하였다. In order to confirm that the expression of immune-related genes is increased as well as cytokine secretion, Raw264.7 cell line was treated with 1% of human milk extract and after 12 hours, the expression level of IFN-ß and antiviral gene was measured by real-time PCR (real time PCR).
그 결과 도 7에 개시한 바와 같이 양성대조군과 마찬가지로, 자완 추출물을 처리한 세포에서 항바이러스 유전자들의 발현량이 증가하였으며, 이와 같은 결과로부터 자완 추출물이 면역증강에 효과가 있다는 것을 재확인하였다.
As a result, as shown in Fig. 7, the expression level of antiviral genes was increased in the cells treated with the extract of chrysanthemum, as in the positive control. From these results, it was confirmed that the chrysanthemum extract had an effect on immunity enhancement.
실시예Example 5. 5. 자완Wisdom 추출물의 처리에 따른 Depending on the treatment of the extract 선천면역Congenital immunity 관련 신호전달 분자들의 발현량 변화 확인 Identification of changes in expression levels of related signaling molecules
인터페론이나 전염증성 사이토카인 등의 분비는 체내에 침입한 바이러스에 대응하는 중요한 선천면역의 기전 요소로, 이들 사이토카인들이 분비되기 위해서는 세포에 자극된 신호들에 반응하는 특정 분자들의 활성화가 중요하므로, 본 실시예 5에서는 세포 내 신호전달 분자들의 활성화 정도를 특정 항체를 이용하여 확인하였다. 상세하게는 자완 추출물을 Raw 264.7 세포주에 처리한 후, 0, 4, 8, 12 시간 후에 세포를 회수하여 웨스턴 블랏 어세이를 수행하였다. 양성 대조군으로 LPS를 사용하였으며, 시간이 지남에 따라 인터페론 신호전달 활성화와 관련이 있는 TBK1(TANK-binding kinase 1), IRF3(Interferon regulatory factor 3) 분자들의 인산화가 증가되는 것을 확인하였고, 면역과 관련된 사이토카인의 분비에 관여하는 NF-κB 신호전달 경로의 활성화가 p65 인산화에 의해 확인되었다(도 8).
Interleukin and proinflammatory cytokines are important mechanisms of innate immune responses to viruses that enter the body. In order for these cytokines to secrete, activation of specific molecules that respond to stimulated signals is important, In Example 5, the degree of activation of intracellular signal transduction molecules was confirmed using a specific antibody. In detail, after treatment with the Raw 264.7 cell line, the cells were collected at 0, 4, 8, and 12 hours, and Western blotting was performed. LPS was used as a positive control, and it was confirmed that phosphorylation of TBK1 (Tank-binding kinase 1) and IRF3 (interferon regulatory factor 3) molecules, which are involved in the activation of interferon signaling, Activation of the NF-κB signaling pathway involved in the secretion of cytokines was confirmed by p65 phosphorylation (FIG. 8).
실시예Example 6. 6. 자완Wisdom 추출물에 의한 By extract H1N1H1N1 및 And H5N2H5N2 바이러스 감염 억제 분석 Virus Infection Inhibition Analysis
(1) 분석방법(1) Analysis method
MDCK 세포주에 자완 추출물과 1.0 MOI(multiplicity of infection) 바이러스를 동시에 처리하고 24시간 후, 세포독성을 측정하기 위하여 10㎕의 Ez-Cytox 시약을 처리하고 12시간 동안 배양하고 450nm에서 흡광도를 측정하였다.
The MDCK cell line was treated with the Zyklonan extract and 1.0 MOI (multiplicity of infection) at the same time. After 24 hours, 10 μl of Ez-Cytox reagent was treated for 12 hours and absorbance was measured at 450 nm to measure cytotoxicity.
(2) 분석결과(2) Analysis results
자완 추출물에 의한 H1N1 및 H5N2 바이러스 감염에 의한 세포 생존도를 분석한 결과, H1N1 및 H5N2 바이러스 감염에 의해 세포 생존률이 약 20%로 감소하였으며, 자완 추출물과 1 MOI 바이러스를 동시에 처리한 군의 경우, 세포 생존률이 약 60%로 나타나, 바이러스 감염에 의한 세포 생존률의 감소를 막아주는 것을 확인하였다(도 9).
The cell viability by H1N1 and H5N2 virus infection was decreased to 20% by H1N1 and H5N2 virus infection. In case of the group treated simultaneously with Wanwan extract and MOI virus, The cell viability was about 60%, and it was confirmed that the cell viability was prevented from decreasing due to the viral infection (Fig. 9).
실시예Example 7. 7. 자완Wisdom 추출물에 의한 By extract InIn vivovivo 항인플루엔자바이러스Anti-influenza virus 효능 검증 Efficacy verification
본 발명의 일 실시예에 따른 자완 추출물의 경구 투여에 의한 In vivo 항인플루엔자바이러스 효능을 분석하였다. 자완 추출물을 Balb/c 마우스에 경구투여하고, 인플루엔자바이러스인 H1N1을 5LD50로 감염시킨 후, 마우스의 생존률(%)을 확인하였다. The efficacy of the in vivo anti-influenza virus by oral administration of the chrysanthemum extract according to one embodiment of the present invention was analyzed. After oral administration of the extract jawan in Balb / c mice, infected with the influenza virus of H1N1 in 5LD 50, it was confirmed in the mice survival rate (%).
그 결과, 도 10에 개시한 바와 같이, 감염 후 9일째 control 그룹에서는 20%의 생존률을 보이는 반면, 자완 추출물을 경구 투여한 그룹에서는 60%의 생존률을 보였다. 이와 같은 결과로부터 자완 추출물에 의한 면역 증강이 마우스를 치사시킬 수 있는 인플루엔자바이러스 감염에 대하여 방어능이 있다는 것을 검증할 수 있었다.
As a result, as shown in Fig. 10, the survival rate was 20% in the control group on the ninth day after infection, and 60% in the oral administration group. From these results, it was verified that the immunity enhancement by the human milk extract is protective against the influenza virus infection which can kill mice.
제조예Manufacturing example 1. 주사제 1. Injection
상기 실시예 1에서 제조한 자완 추출물: 100㎎The human milk extract prepared in Example 1: 100 mg
소듐 메타비설파이트: 3.0㎎Sodium metabisulfite: 3.0 mg
메틸파라벤: 0.8㎎Methylparaben: 0.8 mg
프로필파라벤: 0.1㎎Propyl paraben: 0.1 mg
주사용 멸균 증류수: 적량Sterile sterilized distilled water for injection:
상기 성분을 혼합하고 통상의 방법으로 최종 부피가 2 ㎖이 되도록 제조하여, 앰플에 충전하고 멸균하여 주사제를 제조하였다.
The above ingredients were mixed and made into a final volume of 2 ml by a conventional method, filled in an ampoule and sterilized to prepare an injection.
제조예Manufacturing example 2. 정제 2. Refining
상기 실시예 1에서 제조한 자완 추출물: 200㎎The human milk extract prepared in Example 1: 200 mg
감자 전분: 100㎎Potato starch: 100 mg
락토오스: 100㎎Lactose: 100 mg
콜로이드성 규산: 16㎎Colloidal silicic acid: 16 mg
스테아린산 마그네슘: 적량Magnesium stearate:
통상의 정제 제조방법에 따라 상기 성분을 혼합하고 타정하고 정제를 제조하였다.
The ingredients were mixed and tableted according to a conventional tablet preparation method to prepare tablets.
제조예Manufacturing example 3. 3. 캡슐제Capsule
상기 실시예 1에서 제조한 자완 추출물: 100㎎The human milk extract prepared in Example 1: 100 mg
유당: 50㎎Lactose: 50 mg
전분: 50㎎Starch: 50 mg
탈크: 2㎎Talc: 2 mg
스테아린산 마그네슘: 적량Magnesium stearate:
통상의 캡슐 제조방법에 따라 상기 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
The above components were mixed according to a conventional capsule manufacturing method and filled in gelatin capsules to prepare capsules.
제조예Manufacturing example 4. 4. 환제Pill
상기 실시예 1에서 제조한 자완 추출물: 120㎎The human milk extract prepared in Example 1: 120 mg
옥수수 전분: 100㎎Corn starch: 100 mg
멸균 증류수: 적량Sterilized distilled water: suitable amount
상기 성분을 혼합하고, 통상의 환제 제조방법에 따라 적절한 크기를 갖는 구형으로 제환하여 환제를 제조하였다.
The above ingredients were mixed and pelletized to spheres of appropriate size according to conventional pellet manufacturing methods to produce pellets.
제조예Manufacturing example 5. 건강 기능 식품 5. Health functional foods
1) 건강 음료1) Health drinks
올리고당(2%), 액상과당(0.5%), 설탕(2%), 식염(0.5%), 물(75%) 등의 음료 재료에 상기 실시예 1에서 제조된 자완 추출물을 적량 혼합하여, 살균함으로써 음료를 제조하였다. The honeycomb extract prepared in Example 1 was mixed in an appropriate amount to drink materials such as oligosaccharide (2%), liquid fructose (0.5%), sugar (2%), salt (0.5% To prepare a beverage.
2) 기능성 식품2) Functional food
상기 실시예 1에서 제조한 자완 추출물을 각종 비타민 및 미네랄 함유 기능성 식품에 적량 혼합하여 자완 추출물이 함유된 기능성 식품을 제조하였다.
The functionalized food containing the extract of Zyklonan was prepared by mixing the Zyklonan extract prepared in Example 1 with various vitamins and minerals functional foods in an appropriate amount.
제조예Manufacturing example 6. 사료 조성물 6. Feed composition
동물용 배합 사료에 상기 실시예 1에서 제조된 자완 추출물을 적량 혼합하여, 사료 조성물을 제조한 후, 펠렛화 및 과립화하였다.The animal feed composition was mixed with the chrysanthemum extract prepared in Example 1 in an appropriate amount to prepare a feed composition, which was then pelletized and granulated.
Claims (13)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150042940 | 2015-03-27 | ||
| KR1020150042940 | 2015-03-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160115824A KR20160115824A (en) | 2016-10-06 |
| KR101800443B1 true KR101800443B1 (en) | 2017-11-22 |
Family
ID=57006974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160035813A KR101800443B1 (en) | 2015-03-27 | 2016-03-25 | Composition for enhancing innate immunity and antivirus comprising Asteris Radix extract as effective component |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101800443B1 (en) |
| WO (1) | WO2016159581A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100543355B1 (en) * | 2005-05-17 | 2006-01-20 | 김성호 | A Herb extract |
| CN100434001C (en) * | 2004-11-26 | 2008-11-19 | 李忠 | Aster health-care cigarette with harm decreasement |
| CN103145792A (en) | 2013-03-25 | 2013-06-12 | 中国科学院昆明植物研究所 | Shionone triterpenes as well as pharmaceutical compositions, preparation methods and applications of shionone triterpenes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930000122A (en) * | 1991-06-03 | 1993-01-15 | 김성호 | Treatment of acquired immunodeficiency syndrome (Aequired Immune Deficiency Syndrome) and preparation method thereof |
| KR20040065498A (en) * | 2003-01-14 | 2004-07-22 | 주식회사 엘지생활건강 | Allergic dermatitis and skin itching relieving composition containing natural herb extract |
| CN101181561B (en) * | 2007-12-10 | 2010-11-17 | 金陵药业股份有限公司 | Chinese medicine as well as preparation method and application thereof |
| CN102657804B (en) * | 2012-05-21 | 2014-08-20 | 深圳市齐旺投资有限公司 | Traditional Chinese medical composition for treatment of viral influenza and preparation method thereof |
-
2016
- 2016-03-25 WO PCT/KR2016/003039 patent/WO2016159581A2/en active Application Filing
- 2016-03-25 KR KR1020160035813A patent/KR101800443B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100434001C (en) * | 2004-11-26 | 2008-11-19 | 李忠 | Aster health-care cigarette with harm decreasement |
| KR100543355B1 (en) * | 2005-05-17 | 2006-01-20 | 김성호 | A Herb extract |
| CN103145792A (en) | 2013-03-25 | 2013-06-12 | 中国科学院昆明植物研究所 | Shionone triterpenes as well as pharmaceutical compositions, preparation methods and applications of shionone triterpenes |
Non-Patent Citations (2)
| Title |
|---|
| Evidence-Based Complementary and Alternative Medicine. 2014. Vol.2014, Article ID 976364.* |
| Journal of Ethnopharmacology. 2014. Vol.151, pp.1056-1063.* |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016159581A3 (en) | 2016-12-01 |
| WO2016159581A2 (en) | 2016-10-06 |
| KR20160115824A (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101780975B1 (en) | Composition for enhancing innate immunity and antivirus comprising Pini Pollen extract as effective component | |
| KR101951003B1 (en) | Composition for enhancing innate immunity and antivirus comprising Echinopsis Radix extract as effective component | |
| KR101669988B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Phellodendri Cortex | |
| KR101770573B1 (en) | Composition for enhancing innate immunity and antivirus comprising Schizonepetae Spica extract as effective component | |
| KR101951010B1 (en) | Composition for enhancing innate immunity and antivirus comprising Isatidis Folium extract as effective component | |
| KR101930778B1 (en) | Composition for antivirus comprising Ulmi Cortex extract as effective component | |
| KR101725938B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Coptis japonica (Thunb.) Makino | |
| KR101762606B1 (en) | Composition for enhancing innate immunity and antivirus comprising Foeniculi Fructus extract as effective component | |
| KR101874465B1 (en) | Composition for enhancing innate immunity and antivirus comprising Eupatorii Herba extract as effective component | |
| KR101782847B1 (en) | Composition for enhancing innate immunity and antivirus comprising Hoveniae Semen Cum Fructus extract as effective component | |
| KR101837445B1 (en) | Composition for enhancing innate immunity and antivirus comprising Dianthi Herba extract as effective component | |
| KR101762608B1 (en) | Composition for enhancing innate immunity and antivirus comprising Hoveniae Semen Cum Fructus extract as effective component | |
| KR101837448B1 (en) | Composition for enhancing innate immunity and antivirus comprising Piperis Longi Fructus extract as effective component | |
| KR101951008B1 (en) | Composition for enhancing innate immunity and antivirus comprising Psoraleae Semen extract as effective component | |
| KR101770572B1 (en) | Composition for enhancing innate immunity and antivirus comprising Mori Ramulus or Mori Radicis Cortex extract as effective component | |
| KR20160112831A (en) | Composition for enhancing innate immunity and antivirus comprising Chelidonii herba extract as effective component | |
| KR101800443B1 (en) | Composition for enhancing innate immunity and antivirus comprising Asteris Radix extract as effective component | |
| KR101791036B1 (en) | Composition for enhancing innate immunity and antivirus comprising Melandrii Herba extract as effective component | |
| KR102287633B1 (en) | Composition for enhancing innate immunity and antivirus comprising Puerariae Flos extract as effective component | |
| KR101677119B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Angelicae Tenuissimae Radix | |
| KR101951004B1 (en) | Composition for enhancing innate immunity and antivirus comprising Albizziae Cortex extract as effective component | |
| KR20160104979A (en) | Composition for enhancing innate immunity and antivirus comprising Eriocauli Herba extract as effective component | |
| KR102349860B1 (en) | Composition for enhancing innate immunity and antivirus comprising Benincasae Pericarpium extract as effective component | |
| KR102307757B1 (en) | Composition for enhancing innate immunity and antivirus comprising Typhae pollen extract as effective component | |
| KR20160104978A (en) | Composition for enhancing innate immunity and antivirus comprising Euonymi Lignum Suberalatum extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |